Spectranetics Corp. announced the recent appointment of Maria Sainz and Daniel A. Pelak to its board of directors. The appointments bring the board to nine members. Sainz currently resides as the president and CEO of Concentric Medical Inc., a privately held, commercial stage company that manufactures minimally invasive devices that are delivered into the brain to remove blood clots that can cause ischemic strokes. She has served at the company since 2006. Prior to that, she has held executive positions in the US and Europe within the cardiac rhythm management, cardiac surgery and vascular intervention divisions of Eli Lilly’s medical device businesses and Guidant Corp. She served as a member of the Guidant Management Committee as president of the cardiac surgery division from 2003 to 2006. After Guidant’s acquisition by Boston Scientific Corp. in 2006, Sainz acted as an advisor to the COO, assisting in several transition activities in both the US and Europe. Currently a senior advisor to the private equity firm Welsh, Carson, Anderson and Stowe, Pelak served as the president and CEO of Innerpulse Inc. from 2005 to 2008. Prior to that, he was president and CEO of Closure Medical Corp. He has also held over a 25-year period many management positions at Medtronic Inc. “Both Maria and Dan have demonstrated their ability to grow developing companies and manage corporate operating divisions within the medical device industry,” said R. John Fletcher, chair of the Nominating and Governance Committee of the Spectranetics board of directors. “Their collective operating experience, demonstrated leadership success and medical device industry knowledge will be an outstanding addition to the board of directors at Spectranetics.” Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. For more information, visit: www.spectranetics.com